Enanta dips on concerns about pruritus, differentiation of NASH compound

Dose selection for an upcoming trial could prove crucial among Enanta’s next steps for its FXR agonist following a Phase II readout in NASH that raised questions about the compound’s tolerability and differentiation from others in its class.

Enanta shed more than $200 million in market cap Thursday

Read the full 475 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE